Objective To externally validate, at the national level, a cumulative risk score for vaginal birth after cesarean (VBAC) success and neonatal morbidity derived from single-center data.

Methods We conducted a population based cohort study of all trial of labor after cesarean (TOLAC) attempts among term, singleton deliveries recorded in the Centers for Disease Control and Prevention natality files, 2020 to 2024 (N=477,693). The cumulative risk score (range −1 to 7 points) incorporated body mass index (BMI) 30 or greater (+1), BMI 40 or greater (+1), induction of labor (IOL; +1), diabetes mellitus (+1), hypertensive disorder (+1), maternal age 40 years or older (+1), gestational age 41 weeks or greater (+1), and prior vaginal delivery (−1). VBAC success rates and neonatal intensive care unit (NICU) admission rates were evaluated across risk strata.

Results The overall VBAC rate was 73.3% (350,340/477,693). The cumulative risk score demonstrated a monotonic relationship with VBAC success: score −1, 90.5%; score 0, 76.4%; score 1, 69.4%; score 2, 62.2%; score 3, 55%; and score 4 or higher, 44.8%. NICU admission rates increased concordantly from 43.8 to 111.1 per 1,000 across strata. Prior vaginal delivery was the strongest individual predictor (VBAC 86.4% vs 62.5%). VBAC rates and TOLAC volume were stable across 2020–2024.

Conclusion The cumulative risk score derived from single-center data was externally validated in a national cohort of 477,693 TOLAC attempts. The monotonic dose-response relationship between risk score and both VBAC success and NICU admission was confirmed, supporting the use of this score for individualized TOLAC counseling.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

US natality files were used which are published on the CDC website

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors